Press release
  • 22/05/2018: MElkin Pharmaceuticals welcomes the breakthrough achieved by its academic collaborators in the knowledge of depression, as well as the promising preclinical data of the PepElk compound in the treatment of depression.           Dowload Press Release (pdf)…

Press article
  • 16/11/2017: La lettre d’innovation du CNRS – MElkin Pharmaceuticals : des molécules innovantes pour le traitement de certains cancers.                                                                                                                                                                                       La start-up MElkin Pharmaceuticals développe des peptides synthétiques issus des travaux de recherche menés au laboratoire Neuroscience Paris-Seine au sein de l’Institut Biologie Paris Seine.           Read more…

Publications

Patents
  • Pepsignal Concept 2006 patent, Vanhoutte P, Caboche J. , WO 2006/08724
  • Pepsignal and depression. 2010 paten, Caboche J, Tzavara E, Vanhoutte P, Giros B. , WO2010/037841
  • A Selective inhibitor of c-Fos and their antiproliferative properties. 2014 Patent, Vanhoutte P, Caboche J. , WO201555218.

MElkin Pharmaceuticals